Hikma Pharmaceuticals Share Discussion Threads

[suetballs] 22/8/2022 10:21

blue - you could be ok - new ceo plus generics sorted!
But as I get older I need "safer" shares - if they exist!
Suet

[blue59] 22/8/2022 09:49

I’m tempted to jump but my masochistic streak won’t allow me to.

[suetballs] 22/8/2022 09:19

After holding for many years I have finally given up here.This share is really unloved and I can see it going lower.
Switched to azn.
Shame.
Suet

[blue59] 19/8/2022 15:19

Being manipulated!?

[lombriz] 18/8/2022 21:47

History seems to be repeating itself...Last time, 5 years ago, from memory Barclays issued a £30 target, and the share price promptly finished up at £8. It was a nerve-racking time for investors (including me), before the share price rapidly recovered to £20, largely due to the surprise appointment of an impressive new CEO. The question is, would it rapidly recover this time round? Or would the ending be totally different?

[cumnor] 18/8/2022 20:32

Punters and IIs are tiring of indebted companies like Hikma which paid divis of 2% for past couple of years, promised the earth and fail to deliver, as recent results show. Meanwhile directors pay themselves huge salaries and bonuses but expect investors to pay dear for the measly dividend. This could have been more generous and the recent falls (not just here) in poor payers share prices reflect a change in attitude to greedy directors.
Needs to see a divi of 5% plus before I'd touch this.

[scepticalinvestor] 18/8/2022 16:30

Good grief turning into a bloodbath.Looks like 800 is on the cards again - AVOID

[blue59] 12/8/2022 09:38

Hope you’re right, I doubled down again earlier in the week.

[scepticalinvestor] 12/8/2022 09:14

Haha perhapsLong term hikma will come good. Just looking for the right time to buy back in

[blue59] 12/8/2022 09:04

SI true, but (and this isn’t aimed at you) wouldn’t it just be better not to write bulls##t (and repeating it endlessly) in the first place?

[buy2sell1] 12/8/2022 08:02

Unbelievable !!!! Skeppy Investor has got another one WRONG !!!

Boohoo, Hikma, 4D Pharma

Did you get your charts UPSIDE DOWN again, LOSER BOY !!!

[scepticalinvestor] 11/8/2022 19:28

Sometimes when the situation changes, it pays to change outlook too said yogi berra

[blue59] 11/8/2022 13:50

What about that, much repeated, Barclays 2800 target and the increased (15th straight) dividend???
The bullish pluggers have become bears, must be time to buy!

[scepticalinvestor] 11/8/2022 11:59

Damn shame - excellent track record to date. Ex ceo was driving force, now it is a rudderless boat

[montyhedge] 11/8/2022 09:13

Yes if this is demoted from FTSE 100.Must be close looking at market cap.

[scepticalinvestor] 11/8/2022 08:43

Dumped the last of my holdings here...looks likeits back to the 800s

[mjneish] 05/8/2022 15:12

RMG and ITV both dropped out of the FTSE-100 in June. There doesn't seem to have been a flurry of institutional selling, if you check the RNSs. These are just two examples though.

At any rate, if the price is further depressed by institutional selling, this will create a very nice buy opportunity.

[montyhedge] 05/8/2022 14:06

My worried is will they be demoted from the FTSE 100 index looking at their market cap. Then the FTSE 100 tracker funds would sell.

[mjneish] 04/8/2022 11:11

As generics decline, they form a smaller and smaller proportion of overall revenue. Well at least it doesn't look like earnings will fall off a cliff.

[suetballs] 04/8/2022 10:28

So not too bad. Perhaps.
Suet

[mjneish] 04/8/2022 10:10

There was an error in my previous post that I've corrected. Here's the analysis. I cannot guarantee that it's error free.

----------

2021 Revenue: $2553 million

(injectables $1053 million, generics $820 million, branded $669 million, other $11 million)

2021 Core operating profit: $632 million

Outlook - injectables

Expected revenue growth in middle to high single digits.
Core operating margin expected to be 36% to 37%

Assuming 5% and 36% respectively, this gives a full-year revenue of $1106 million and core operating profit of $398 million.

Outlook – branded

Expected revenue growth in the low single digits.
No guidance provided on core operating margin.

Assuming 3% revenue growth (pure guess) and the same core operating margin as last year, this give a full-year revenue of $689 million and core operating profit of $150 million.

Outlook – generics

Expected revenue $650 million to $675 million.
Core operating margin expected to be 15% to 16%.

Assuming revenue of $650 million and core operating margin of 15%, this gives a core operating profit of $98 million.

Overall revenue for 2022 is $2445 million and core operating profit $646 million.

Summary

Full-year revenue falls from $2553 million in 2021 to $2445 million.
Core operating profit rises from $632 million to $646 million.

[adamb1978] 04/8/2022 10:06

Even taking historic earnings, PE is only around 11x. It feels like there's a lot of negativity built into the share price here. To justify this sort of multiple, you need to believe that the business is going to be more of less flat going forwards

No investment is a sure thing, and they're all an assessment of upside and downside potential. It feels to me that the multiple provides for a lot of downside protection here, and probably far too much

[phillis] 04/8/2022 09:59

you are the veritable kiss of death Monty